Expression of peroxisome proliferator activated receptor-gamma (PPAR-γ) in human non-small cell lung carcinoma: Correlation with clinicopathological parameters, proliferation and apoptosis related molecules and patients' survival

Pathology and Oncology Research

Volumn 18, Issue 4, 2012, Pages 875-883

  Giaginis, Costantinos ^a,b   Politi, Ekaterini ^a,c   Alexandrou, Paraskevi ^a   Sfiniadakis, John ^c   Kouraklis, Gregory ^a   Theocharis, Stamatios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF THE AEGEAN   (Greece)

^c ATHENS NAVAL HOSPITAL   (Greece)

Author keywords

Apoptosis; Cell cycle; Cell proliferation; Immunohistochemistry; Non small cell lung carcinoma; PPAR

Indexed keywords

KI 67 ANTIGEN; MYC PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PREDICTION; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL GROWTH PROCESSES; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PPAR GAMMA; SURVIVAL RATE;

EID: 84868381137     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-012-9517-9     Document Type: Article

References (65)

1. Willson TM, Brown PJ, Strenbach DD, Henke BR (2000) The PPARs: From orphan receptors to drug discovery. J Med Chem 43:527-550.
2. Berger J, Moller DE (2002) The mechanisms of action of PPARs. Ann Rev Med 53: 409-435.
3. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV (1998) Ligand binding and co-activator assembly of the peroxisome proliferators activated receptor-γ. Nature 395:137-143.
4. Fajas L, Auboeuf D, Raspe E, Shoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J (1997) The organization, promoter analysis and expression of the human PPARγ gene. J Biol Chem 272:18779-1878.
5. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W (2006) From: molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45:120-159.
6. Desvergne B, Wahli W (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20:649-688.
7. Hamza MS, Pott S, Vega VB, Thomsen JS, Kandhadayar GS, Ng PW, Chiu KP, Pettersson S,Wei CL, Ruan Y, Liu ET (2009) De-novo identification of PPARgamma/RXR binding sites and direct targets during adipogenesis. PLoS One 4:e4907.
8. Wysowski DK, Armstrong G, Governale L (2003) Rapid increase in the use of oral Antidiabetic drugs in the United States, 1990-2001. Diabetes Care 26:1852-1855.
9. Sugden MC, Zariwala MG, Holness MJ (2009) PPARs and the orchestration of metabolic fuel selection. Pharmacol Res 60:141-150.
10. Panigraphy D, Huang S, Kieran MW, Kaipainen A (2005) PPARγ as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther 4:687-693.
11. Giaginis C, Tsantili-Kakoulidou A, Theocharis S (2008) Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) ligands: potential pharmacological agents for targeting the angiogenesis signaling cascade in cancer. PPAR Res 2008:431763.
12. Theocharis S, Margeli A, Vielh P, Kouraklis G (2004) Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators. Cancer Treat Rev 30:545-554.
13. Giaginis C, Tsantili-Kakoulidou A, Theocharis S (2007) Peroxisome proliferator activated receptor-gamma ligands as bone turnover modulators. Expert Opin Investig Drugs 16:195-207.
14. Rizzo G, Fiorucci S (2006) PPARs and other nuclear receptors in inflammation. Curr Opin Pharm 6:421-427.
15. Giaginis C, Tsourouflis G, Theocharis S (2008) Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injury. Curr Mol Med 8:562-579.
16. Giaginis C, Spanopoulou E, Theocharis S (2008) PPAR-gamma signaling pathway in placental development and function: a potential therapeutic target in the treatment of gestational diseases. Expert Opin Ther Targets 12:1049-1063.
17. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300.
18. D'Addario G, Felip E (2009) Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20:68-70.
19. Méndez D, Alshanqeety O, Warner KE, Lantz PM, Courant PN (2011) The impact of declining smoking on radon-related lung cancer in the United States. Am J Public Health 101:310-314
20. Alberg AJ, Brock MV, Samet JM (2005) Epidemiology of lung cancer: looking to the future. J Clin Oncol 23:3175-3185.
21. Nemenoff RA, Winn RA (2005) Role of nuclear receptors in lung tumourigenesis. Eur J Cancer 41:2561-2568.
22. Keshamouni VG, Han S, Roman J (2007) Peroxisome proliferatoractivated receptors in lung cancer. PPAR Res 2007:90289
23. Tsubouchi Y, San H, Kawahito Y Mukai S, Yamada R, Kohno M, Inoue K, Hla T, Kondo M (2000) Inhibition of human cancer cell growth by peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 270:400-405.
24. Keshamouni VG, Reddy RC, Arenberg DA, Joel B, Thannickal VJ, Kalemkerian GP, Standiford TJ (2004) Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 23:100-108.
25. Allred CD, Kilgore MW (2005) Selective activation of PPARγ in breast, colon, and lung cancer cell lines. Mol Cell Endocrinol 235:21-29.
26. Chang TH, Szabo E (2000) Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non small cell lung cancer. Cancer Res 60:1129-1138.
27. InoueK,KawahitoY, TsubouchiY, Yamada R,KohnoM, Hosokawa Y, Katoh D, Bishop-Bailey D, Hla T, Sano H (2001) Expression of peroxisome proliferator-activated receptor (PPAR)-gamma in human lung cancer. Anticancer Res 21:2471-2476.
28. Sasaki H, Tanahashi M, Yukiue H, Moiriyama S, Kobayashi Y, Nakashima Y, Kaji M, Kiriyama M, Fukai I, Yamakawa Y, Fujii Y (2002) Decreased peroxisome proliferator-activated receptorgamma gene expression was correlated with poor prognosis in patients with lung cancer. Lung cancer 36:71-76.
29. Theocharis S, Kanelli H, Politi E, Margeli A, Karkandaris C, Philippides T, Koutselinis A (2002) Expression of peroxisome proliferator-activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade. Lung Cancer 36:249-255.
30. Wick M, Hurteau G, Dessev C, Chan D, Geraci MW, Winn RA, Heasley LE, Nemenoff RA (2002) Peroxisome proliferatoractivated receptor-gamma is a target of nonsteroidal antiinflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol 62:1207-1214.
31. Han S, Sidell N, Fisher PB, Roman J (2004) Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor γ in human lung carcinoma cells. Clin Cancer Res 10:1911-1919.
32. Li M, Lee TW, Mok TSK,Warner TD, Yim APC, Chen GG (2005) Activation of peroxisome proliferator-activated receptor-γ by troglitazone (TGZ) inhibits human lung cell growth. J Cell Biochem 96:760-774.
33. Li M, Lee TW, Yim AP, Mok TS, Chen GG (2006) Apopotsis induced by troglitazone is both peroxisome proliferator-activated receptor-γ- and ERK-dependent in human non-small cell lung cancer cells. J Cell Physiol 209:428-438.
34. Zou W, Liu X, Yue P, Khuri FR, Sun SY (2007) PPARg ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. Cancer Biol Ther 6:99-106.
35. Keshamouni VG, Arenberg DA, Reddy RC, Newstead MJ, Anthwal S, Standiford TJ (2005) PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. Neoplasia 7:294-301.
36. Bren-Mattison Y, Van Putten V, Chan D, Winn R, Geraci MW, Nemenoff RA (2005) Peroxisome proliferator-activated receptorgamma (PPARgamma) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene 24:1412-1422.
37. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ, Lang NP (2007) Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 25:1476-1481.
38. Greene FLPD, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M (2002) AJCC cancer staging manual, 6th edn. Springer, New York
39. Nair A, Klusmann MJ, Jogeesvaran KH, Grubnic S, Green SJ, Vlahos I (2011) Revisions to the TNM Staging of Non-Small Cell Lung Cancer: Rationale, Clinicoradiologic Implications, and Persistent Limitations. Radiographics 31:215-238.
40. Lababede O, Meziane M, Rice T (2011) Seventh edition of the cancer staging manual and stage grouping of lung cancer: quick reference chart and diagrams. Chest 139:183-189.
41. Giaginis C, Katsamangou E, Tsourouflis G, Zizi-Serbetzoglou D, Kouraklis G, Theocharis S (2009) Peroxisome proliferatoractivated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival. Med Sci Monit 15: BR148-156.
42. Theocharis S, Giaginis C, Parasi A, Margeli A, Kakisis J, Agapitos E, Kouraklis G (2007) Expression of Peroxisome Proliferator- Activated Receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle related molecules and patients' survival. Dig Dis Sci 52:2305-2311.
43. Ondrey F (2009) Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res 15:2-8.
44. Sultana H, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Sato S, Kamazawa S, Ohwada M, Suzuki M, Terakawa N (2003) Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients with uterine cervical cancer. Ann Oncol 14:214-219.
45. Kirkin V, Joos S, Zornig M (2004) The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 1644:229-249
46. Yang FG, Zhang ZW, Xin DQ, Shi CJ, Wu JP, Guo YL, Guan YF (2005) Peroxisome proliferator-activated receptor γ ligands induce cell cycle arrest and apoptosis in human renal cell carcinoma cell lines. Acta Pharmacol. Sin 26:753-761.
47. Liu JJ, Huang RW, Lin DJ, Peng J, Wu XY, Lin Q, Pan XL, Song YQ, Zhang MH, Hou M, Chen F (2005) Expression of surviving and bax/bcl-2 in peroxisome proliferator activated receptor γ ligands induces apoptosis on human myeloid leukemia cells in vitro. Ann Oncol 16:455-459.
48. Liu DC, Zang CB, Liu HY, Possinger K, Fan SG, Elstner E (2004) A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells. Acta Pharmacol Sin 25:1312-1319.
49. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP (1998) Ligands for peroxisome proliferator activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95:8806-8811.
50. Strakova N, Ehrmann J, Bartos J, Malikova J, Dolezel J, Kolar Z (2005) Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of gliab brain tumors. Neoplasma 52:126-136.
51. Shimada T, Kojima K, Yoshiura K, Hiraishi H, Terano A (2002) Characteristics of the peroxisome proliferator activated receptor γ (PPARγ) ligand induced apoptosis in colon cancer cells. Gut 50:658-664.
52. Fulzele SV, Chatterjee A, Shaik MS, Jackson T, Ichite N, Singh M (2007) 15-deoxy-detal 12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non small cell lines and xenograft tumors. Anticancer Drugs 18:65-78.
53. Yamakawa-KarakidaN, SugitaK, Inukai T, GoiK,NakamuraM,Uno K, Sato H, Kagami K, Barker N,Nakazawa S (2002) Ligand activation of peroxisome proliferator activated receptor γ induces apoptosis of leukemia cells by down-regulating the c-myc gene expression via blockage of the Tcf-4 activity. Cell death Diff 9:513-526.
54. Sikand K, Kaul D, Varma N (2006) Receptor Ck-dependent signaling regulates hTERT gene transcription. BMC Cell Biology 7:2.
55. Han SW, Greene ME, Pitts J, Wada RK, Sidell N (2001) Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARgamma) in human neuroblastoma cells. Clin Cancer Res 7:98-104.
56. Zhang GY, Ahmed N, Riley C et al. (2005) Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. Br J Cancer 92:113-119.
57. Lee TW, Chen GG, Xu H, Yip JH, Chak EC, Mok TS, Yim AP (2003) Differential expression of inducible nitric oxide synthase and peroxisome proliferator-activated receptor γ in non-small cell lung carcinoma. Eur J Cancer 39:1296-301.
58. Kim HJ, Hwang JY, Kim HJ, Choi WS, Lee JH, Kim HJ, Chang KC, Nishinaka T, Yabe-Nishimura C, Seo HG (2007) Expression of a peroxisome proliferator- activated receptor gamma 1 splice variant that was identified in human lung cancers suppresses cell death induced by cisplatin and oxidative stress. Clin Cancer Res 13:2577-2583.
59. Jiang WG, Redfern A, Bryce RP, Mansel RE (2000) Peroxisome proliferator activated receptor-gamma (PPAR-gamma) mediates the action of gamma linolenic acid in breast cancer cells. Prostaglandins Leukot Essent Fatty Acids 62:119-127.
60. Katagiri Y, Takeda K, Yu ZX, Ferrans VJ, Ozato K, Guroff G (2000) Modulation of retinoid signaling through NGF-induced nuclear export of NGFI-B. Nat Cell Biol 2:435-440.
61. Ikezoe T, Miller CW, Kawano S, Heaney A, Williamson EA, Hisatake J, Green E, Hofmann W, Taguchi H, Koeffler HP (2001) Mutational analysis of the peroxisome proliferatoractivated receptor γ gene in human malignancies. Cancer Res 61:5307-5310.
62. Sun Y (2006) p53 and its downstream proteins as molecular targets of cancer. Mol Carcinog 45:409-415.
63. Breuer RH, Postmus PE, Smit EF (2005) Molecular pathology of non-small-cell lung cancer. Respiration 72:229-232.
64. Viktorsson K, De Petris L, Lewensohn R (2005) The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun 331:868-880.
65. Martin B, Paesman SM, Mascaux C, Berghmans T, Lothaire P, Meert A-P, Lafitte J-J, Sculier J-P (2004) Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 91:2018-2025